Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation)

Rahman, Syed T.; Lauten, Wright B.; Khan, Qamar Alam; Navalkar, Sushant; Parthasarathy, S.; Khan, Bobby V.

doi:10.1016/s0002-9149(01)02340-2

Cited by 62 publications

(35 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients were recruited from the Internal Medicine outpatient clinics and by newspaper advertise- Effects of different classes of antihypertensive drugs on endothelial function Only short-term studies (4-12 weeks of antihypertensive treatment) [7][8][9][10] Only one study in type II diabetes showed that an ACE-inhibitor could decrease sVCAM-1, not sICAM-1 8 Only one study showed no change in sVCAM-1 levels after hydrochlorothiazide treatment for 4 weeks 7 AT1 receptor antagonists were shown to improve endothelial function in the elderly 9 AT1 receptor antagonists were shown to improve or have no effect on endothelial function in hypertensive individuals 7,10 ACE-inhibitor can improve endothelial function in hypertensive individuals 10 Effects of different classes of antihypertensive drugs on inflammation ACE-inhibitors have no effect on ICAM-1 levels in type II diabetes 8 and can improve ICAM-1 levels in hypertensive individuals 10 AT1 receptor antagonists can either improve or have no effect on sICAM-1 levels 9,10 What knowledge does this paper add …”

Section: Subjectsmentioning

confidence: 99%

“…Several studies have shown that antihypertensive therapies can improve endothelial function and inflammatory activity. [7][8][9][10] However, the effect of aggressive antihypertensive treatment on endothelial function and inflammation in type II diabetes is unknown. In addition, it is unknown whether aggressive antihypertensive therapy based on different classes of antihypertensive drugs has differential effects on these processes (see also Table 1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial

et al. 2005

View full text Add to dashboard Cite

We investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals. A total of 70 hypertensive type II diabetic individuals were treated with three antihypertensive strategies in a randomized, double-blind, double-dummy design. Blood pressure was titrated to levels below 130/85 mmHg or a decrease in systolic pressure of 10% with a diastolic pressure below 85 mmHg. After titration, patients were treated for 12 months. Mean blood pressures changed from 157/93, 151/94 and 149/93 at baseline to 135/80, 135/82 and 131/80 mmHg after titration in the hydrochlorothiazide (n ¼ 24), candesartan (n ¼ 24) and lisinopril (n ¼ 22) groups. About 70% reached target blood pressures. However, only 45% had blood pressures o130/85 mmHg. Urinary albumin excretion and levels of soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 decreased (GEE regression coefficients, À2.40 mg/24 h (Po0.001), À85 ng/ml (P ¼ 0.01) and À50 ng/ml (P ¼ 0.02)), but brachial artery endotheliumdependent and -independent vasodilation and levels of von Willebrand factor and C-reactive protein did not change (GEE regression coefficients, 0.21 mm (P ¼ 0.07), 0.04 mm (P ¼ 0.43), 0.04 IU/ml (P ¼ 0.33) and À1.15 mg/l (P ¼ 0.64)). No differences in outcome variables between treatment groups were observed. These data show that achievement of target blood pressures below 130/ 85 mmHg in hypertensive type II diabetes is difficult. Aggressive antihypertensive therapy can improve urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals, regardless of the type of antihypertensive therapy used.

show abstract

Section: Subjectsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial

et al. 2005

View full text Add to dashboard Cite

show abstract

“…While regular postpartum GTT is universally recommended for the early diagnosis of diabetes in women with GDM (1), these results suggest that perhaps postpartum CRP screening might also have a role in the future. The emergence of data that suggest that part of the cardioprotective benefit of statins and renin-angiotensin system blockers is conferred by antiinflammatory effects would support this approach (42,43). Furthermore, thiazolidinediones and metformin, which increase insulin sensitivity, also reduce CRP levels (44), suggesting an additional potential benefit of these agents in this population.…”

mentioning

confidence: 99%

First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes

et al. 2003

View full text Add to dashboard Cite

OBJECTIVE -Systemic inflammation is associated with the development of type 2 diabetes. We tested the hypothesis that increased inflammation, measured early in pregnancy, is associated with the subsequent development of gestational diabetes mellitus (GDM), a precursor of type 2 diabetes.RESEARCH DESIGN AND METHODS -We conducted a prospective nested casecontrol study in a pregnancy cohort. First-trimester C-reactive protein (CRP) levels were measured using a high-resolution assay in 43 women who subsequently developed GDM and in a random sample of 94 women who remained euglycemic throughout pregnancy. Median CRP levels were compared using Wilcoxon's rank-sum test. Logistic regression was used to compute unadjusted and multivariable-adjusted odds ratios for developing GDM among CRP tertiles.RESULTS -First-trimester CRP levels were significantly increased among women who subsequently developed GDM compared with control subjects (3.1 vs. 2.1 mg/l, P Ͻ 0.01). The risk of developing GDM among women in the highest CRP tertile compared with the lowest tertile was 3.2 (95% CI 1.2-8.8). After adjusting for age, race/ethnicity, smoking, parity, blood pressure, and gestational age at CRP sampling, the risk of developing GDM among women in the highest compared with the lowest tertile was 3.6 (95% CI 1.2-11.4). When BMI was included in the model, however, the association between increased CRP and GDM was attenuated (odds ratio for the highest compared with lowest tertile 1.5 [95% CI 0.4 -5.5]).CONCLUSIONS -In women who develop GDM, there is evidence of increased inflammation during the first trimester. This association is mediated in part by increased BMI. Larger studies are needed to verify these results.

show abstract

“…Interestingly, eprosartan increased by 24% the time needed to produce oxidative byproducts, while 8-epiPGF2a levels remained unchanged. The increase of the lag time for LDL oxidation has been previously reported in patients with mild to moderate essential hypertension, and was attributed to the modulation of NADH/NADPH oxidase, which counteracts superoxide production [16].…”

Section: Discussionmentioning

confidence: 64%

Effects of Eprosartan on Serum Metabolic Parameters in Patients with Essential Hypertension

Rizos¹,

Spyrou²,

Liberopoulos³

et al. 2007

TOCMJ

View full text Add to dashboard Cite

Abstract:The effect of the anti-hypertensive drug eprosartan on metabolic parameters is currently not extensively documented. We evaluated the effect of eprosartan on parameters involved in atherogenesis, oxidative stress and clotting activity. This open-label unblinded intervention study included 40 adult patients with essential hypertension taking eprosartan. Eprosartan significantly reduced by 8% (p<0.001) the systolic and by 13% (p<0.001) the diastolic blood pressure, and increased by 24% the time needed to produce oxidative by-products (p=0.001), a marker of oxidative stress. In contrast, eprosartan did not alter 8-isoprostane (8-epiPGF2a) levels, another marker of oxidative stress. Additionally, eprosartan reduced by 14% aspartate aminotransferase and by 21% then alanine aminotransferase activity, while it had a neutral effect on the lipid profile and apolipoprotein levels and did not influence glucose homeostasis, creatinine and uric acid levels. Eprosartan did not affect the clotting/fibrinolytic status (estimated by plasminogen activator inhibitor 1, tissue plasminogen activator and a2 antiplasmin levels), or the enzymatic activity of the lipoprotein associated phospholipase A2 (Lp-PLA2) and paraoxonase 1 (PON1). In conclusion, eprosartan should be mainly considered as an anti-hypertensive agent with neutral effects on most of the metabolic parameters in hypertensive patients.

show abstract

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation)

Cited by 62 publications

References 18 publications

Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial

Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial

First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes

Effects of Eprosartan on Serum Metabolic Parameters in Patients with Essential Hypertension

Contact Info

Product

Resources

About